CL2020002604A1 - Ciertos compuestos de pladienolida y métodos de uso. - Google Patents

Ciertos compuestos de pladienolida y métodos de uso.

Info

Publication number
CL2020002604A1
CL2020002604A1 CL2020002604A CL2020002604A CL2020002604A1 CL 2020002604 A1 CL2020002604 A1 CL 2020002604A1 CL 2020002604 A CL2020002604 A CL 2020002604A CL 2020002604 A CL2020002604 A CL 2020002604A CL 2020002604 A1 CL2020002604 A1 CL 2020002604A1
Authority
CL
Chile
Prior art keywords
compounds
methods
useful
certain
pladienolide compounds
Prior art date
Application number
CL2020002604A
Other languages
English (en)
Inventor
Kazunobu Kira
Satoshi Nagao
Sonobe Regina Mikie Kanada
Masayuki Miyano
Norio Murai
Andrew Cook
Shelby Ellery
Atsushi Endo
James Palacino
Dominic Reynolds
Gregg F Keaney
John Wang
Baudouin Gerard
Kenzo Arai
Xiang Liu
Guo Zhu Zheng
Lisa A Marcaurelle
Marta Nevalainen
Ming-Hong Hao
Morgan Welzel O'shea
Parcharee Tivitmahaisoon
Sudeep Prajapati
Touping Luo
Nicholas C Gearhart
Jason T Lowe
Yoshihiko Kotake
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2020002604A1 publication Critical patent/CL2020002604A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente divulgación proporciona compuestos de pladienolida novedosos, composiciones farmacéuticas que contienen dichos compuestos, y métodos para usar los compuestos como agentes terapéuticos. Estos compuestos pueden ser útiles en el tratamiento de cánceres, particularmente cánceres en los que se sabe que son útiles los agentes que se dirigen al espliceosoma y las mutaciones en el mismo. También se proporcionan en el presente documento métodos para tratar cánceres mediante la administración de al menos un compuesto divulgado en el presente documento y al menos una terapia adicional.
CL2020002604A 2018-04-09 2020-10-08 Ciertos compuestos de pladienolida y métodos de uso. CL2020002604A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862655021P 2018-04-09 2018-04-09
US201862679653P 2018-06-01 2018-06-01
US201962814838P 2019-03-06 2019-03-06
US201962814843P 2019-03-06 2019-03-06

Publications (1)

Publication Number Publication Date
CL2020002604A1 true CL2020002604A1 (es) 2021-01-15

Family

ID=66248768

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2020002604A CL2020002604A1 (es) 2018-04-09 2020-10-08 Ciertos compuestos de pladienolida y métodos de uso.
CL2022000458A CL2022000458A1 (es) 2018-04-09 2022-02-24 Ciertos compuestos de pladienolida y métodos de uso. (divisional de solicitud 202002604)
CL2023002549A CL2023002549A1 (es) 2018-04-09 2023-08-29 Ciertos compuestos de pladienolida y métodos de uso (divisional).

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2022000458A CL2022000458A1 (es) 2018-04-09 2022-02-24 Ciertos compuestos de pladienolida y métodos de uso. (divisional de solicitud 202002604)
CL2023002549A CL2023002549A1 (es) 2018-04-09 2023-08-29 Ciertos compuestos de pladienolida y métodos de uso (divisional).

Country Status (19)

Country Link
US (3) US11926619B2 (es)
EP (1) EP3774759A2 (es)
JP (3) JP7335265B2 (es)
KR (2) KR102950201B1 (es)
CN (2) CN113166091A (es)
AU (3) AU2019251096B2 (es)
BR (1) BR112020020792A2 (es)
CA (1) CA3096400A1 (es)
CL (3) CL2020002604A1 (es)
CO (1) CO2020013834A2 (es)
IL (3) IL312725A (es)
JO (2) JOP20200242A1 (es)
MX (3) MX2020010606A (es)
PE (1) PE20212327A1 (es)
PH (1) PH12020500666A1 (es)
SG (1) SG11202009906TA (es)
TW (3) TWI863903B (es)
UA (1) UA128864C2 (es)
WO (1) WO2019199667A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119405833A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
PH12021500034A1 (en) 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
EP4161966A1 (en) * 2020-06-05 2023-04-12 Eisai R&D Management Co., Ltd. Anti-bcma antibody-drug conjugates and methods of use
US20240043928A1 (en) 2020-11-04 2024-02-08 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
CN115414351B (zh) * 2022-09-19 2024-05-17 山东大学齐鲁医院 pladienolide B与PD-L1抗体组合在肿瘤免疫治疗领域的应用
MA71743A (fr) * 2022-11-07 2025-05-30 Eisai R&D Management Co., Ltd. Procédé de production d'un composé macrolide

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
NZ322175A (en) 1995-11-10 1999-02-25 Elan Corp Plc Peptides which enhance transport across tissues and methods of identifying the same
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
TWI312681B (en) * 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
US7576204B2 (en) 2002-07-31 2009-08-18 Mercian Corporation Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same
RU2338741C2 (ru) 2002-07-31 2008-11-20 Мершан Корпорейшн Новые физиологически активные вещества
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
RU2330069C2 (ru) 2002-11-29 2008-07-27 Мершан Корпорейшн Способ получения макролидного соединения и штаммы streptomyces sp., mortierella sp. и micromonosporaceae
CN1886505A (zh) 2003-11-27 2006-12-27 美露香株式会社 参与大环内酯类化合物的羟化作用的dna
ATE469985T1 (de) 2004-02-06 2010-06-15 Eisai R&D Man Co Ltd Verfahren zur untersuchung der empfindlichkeit einer krebszelle gegenüber einem antikrebsmittel
CN1977046A (zh) 2004-07-20 2007-06-06 卫材R&D管理有限公司 编码参与普拉地内酯生物合成的多肽的dna
WO2007110704A2 (en) 2005-09-28 2007-10-04 Novimmune Sa Macrolide compositions as therapeutic agent
WO2007110705A2 (en) * 2005-09-28 2007-10-04 Novimmune Sa Macrolide as inhibitors of mhc class ii
CN101282967B (zh) 2005-10-13 2011-01-26 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
JPWO2008020584A1 (ja) * 2006-08-14 2010-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定な凍結乾燥製剤
US7790887B2 (en) 2007-01-29 2010-09-07 Eisai R&D Management Co., Ltd. Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
WO2009008492A1 (ja) 2007-07-06 2009-01-15 Eisai R & D Management Co., Ltd. マクロライド系化合物の製造方法およびその製造中間体
GB0821539D0 (en) * 2008-11-25 2008-12-31 Merlion Pharmaceuticals Pte Ltd Therapeutic compounds and their use
WO2013148324A1 (en) 2012-03-26 2013-10-03 The Regents Of The University Of California Anti-cancer polyketide compounds
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US20140275010A1 (en) 2013-03-12 2014-09-18 Guo Zhu Zheng Quaternary salts
RS58400B1 (sr) 2014-05-15 2019-04-30 Eisai R&D Man Co Ltd Jedinjenja pladienolid piridina i postupci primene
CN106604933B (zh) 2014-07-11 2021-08-10 文塔纳医疗系统公司 抗pd-l1抗体及其诊断用途
EP3344780B1 (en) * 2015-09-01 2021-06-23 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic sf3b1 mutants
IL259198B2 (en) 2015-11-18 2023-04-01 Eisai R&D Man Co Ltd A solid form of paladinolide pyridine compound and methods of its use
IL278740B2 (en) * 2018-06-01 2024-01-01 Eisai R&D Man Co Ltd Methods for using splicing modulators

Also Published As

Publication number Publication date
WO2019199667A2 (en) 2019-10-17
US20210163456A1 (en) 2021-06-03
MX2020010606A (es) 2021-01-15
KR20260049879A (ko) 2026-04-14
TWI878153B (zh) 2025-03-21
AU2019251096A1 (en) 2020-11-26
US20250333400A1 (en) 2025-10-30
CN119462594A (zh) 2025-02-18
US11926619B2 (en) 2024-03-12
CN113166091A (zh) 2021-07-23
KR102950201B1 (ko) 2026-04-10
CO2020013834A2 (es) 2020-12-10
TW202547836A (zh) 2025-12-16
AU2025200844A1 (en) 2025-02-27
TW201945351A (zh) 2019-12-01
JP2025163034A (ja) 2025-10-28
US20240368140A1 (en) 2024-11-07
JOP20200243A1 (ar) 2020-09-29
JP7741142B2 (ja) 2025-09-17
IL312725A (en) 2024-07-01
SG11202009906TA (en) 2020-11-27
JP2021521124A (ja) 2021-08-26
CA3096400A1 (en) 2019-10-17
JOP20200242A1 (ar) 2020-09-29
MX2022015216A (es) 2023-01-04
AU2023202358A1 (en) 2023-05-18
JP7335265B2 (ja) 2023-08-29
EP3774759A2 (en) 2021-02-17
BR112020020792A2 (pt) 2021-01-12
IL303335B1 (en) 2024-09-01
IL277749B2 (en) 2023-11-01
MX2023009976A (es) 2023-10-30
CL2022000458A1 (es) 2022-10-21
PH12020500666A1 (en) 2021-07-26
JP2023156456A (ja) 2023-10-24
AU2023202358B2 (en) 2024-11-07
IL277749B1 (en) 2023-07-01
AU2019251096B2 (en) 2023-04-20
KR20210006907A (ko) 2021-01-19
PE20212327A1 (es) 2021-12-14
IL303335A (en) 2023-07-01
WO2019199667A3 (en) 2019-11-21
UA128864C2 (uk) 2024-11-13
IL303335B2 (en) 2025-01-01
TW202504898A (zh) 2025-02-01
IL277749A (en) 2020-11-30
CL2023002549A1 (es) 2024-01-26
TWI863903B (zh) 2024-12-01

Similar Documents

Publication Publication Date Title
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
CL2020002605A1 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer.
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CO2022010241A2 (es) Inhibidores de sos1
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
MX2021009673A (es) Moduladores de ror-gamma.
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
AR100431A1 (es) Compuestos de pladienolida piridina y métodos de uso
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
CR20190361A (es) Dendrímeros terapéuticos
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
MX2021004566A (es) Compuestos terapeuticos.
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX2018013519A (es) Inhibidores del potenciador del homologo zeste 2.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1